

**Washington State Pharmacy and Therapeutics Committee  
Drug Utilization Review Board  
Date: December 18, 2019  
Time: 9 a.m. to 4 p.m.  
Port of Seattle “International A” Conference Room  
Seattle-Tacoma International Airport  
17801 International Blvd., Seattle, WA 98158**

9 a.m.	Welcome & Introductions  Committee vote on new chair starting 1/1/2020  <b>Pharmacy &amp; Therapeutics Committee Convenes</b>	Lisa Chew, Committee Chair
9:05 a.m.	Atypical Antipsychotics- surveillance report Antipsychotics 2 <sup>nd</sup> Generation <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• P&amp;T Motion</li> </ul>	Brittany Lazur, DERP Umang Patel, Magellan
9:50 a.m.	CGRP- surveillance report Antimigraine Agents: CGRP <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• P&amp;T Motion</li> </ul>	Curtis Harrod, DERP Umang Patel, Magellan
10:30 a.m.	<b>Pharmacy &amp; Therapeutics Committee Adjourns Break</b>	Lisa Chew, Committee Chair All
10:40 a.m.	<b>Drug Utilization Review (DUR) Board Convenes</b>	Lisa Chew, Committee Chair
10:40 a.m.	Antipsychotics 1 <sup>st</sup> Generation <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motions (1<sup>st</sup> gen and 2<sup>nd</sup> gen)</li> </ul>	Umang Patel, Magellan
10:55 a.m.	Antimanic Agents (Lithium Agents) Equetro (Anticonvulsant) <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motions</li> </ul>	Umang Patel, Magellan
11:10 a.m.	Migraine Agents (Antimigraine Agents: Triptans & Other) <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motions</li> </ul>	Umang Patel, Magellan
11:35 a.m.	Antihypertensives (Angiotensin Modulators, Beta Blockers, Calcium Channel Blockers, Diuretics) <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
12:15 p.m.	<b>Lunch</b>	All
12:45 p.m.	Cardiovascular Agents: <ul style="list-style-type: none"> <li>- Nitrates (Coronary Vasodilators)</li> <li>- Sinus Node Inhibitors</li> <li>- Pulmonary Hypertension (PAH Agents, Oral and Inhaled) <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul> </li> </ul>	Umang Patel, Magellan
1:15 p.m.	Bone Density Regulators (Bone Resorption Inhibitors) <ul style="list-style-type: none"> <li>• Stakeholder input*</li> </ul>	Umang Patel, Magellan

Apple Health PDL Drug Class name (Magellan drug class in parenthesis)

*\* Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby.  
Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions  
please call Leta Evaskus at 206-521-2029.

	<ul style="list-style-type: none"> <li>• Motion</li> </ul>	
1:35 p.m.	Antiemetics / Antivertigo Agents <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
1:50 p.m.	Substance Use Disorder (Opiate Dependence) <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
2:10 p.m.	<b>Break</b>	All
2:20 p.m.	Prostatic Hypertrophy Agents (BPH Agents) <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
2:35 p.m.	Androgens : Testosterone (Androgenic Agents) <ul style="list-style-type: none"> <li>• Stakeholder input*</li> <li>• Motion</li> </ul>	Umang Patel, Magellan
3 p.m.	<b>Drug Utilization Review Board Adjourns</b>	Lisa Chew, Committee Chair
3 p.m.	<b>Emerging Therapies Workgroup Overview</b> <ul style="list-style-type: none"> <li>• Stakeholder questions and comments</li> </ul>	Judy Zerzan, HCA
4 p.m.	<b>Meeting Adjourns</b>	All

Apple Health PDL Drug Class name (Magellan drug class in parenthesis)

*\* Stakeholders will be allowed 3 minutes for comments. Stakeholder sign in sheets are in the lobby. Committee discussion and motions will follow stakeholder comments.*

The times noted are estimates and subject to change.

If you are a person with a disability and need a reasonable accommodation or have questions please call Leta Evaskus at 206-521-2029.